Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive randomized controlled platform trial for community-acquired pulmonary infections including COVID-19
MOH_2022-08-14_009900Phase 3Not yet recruiting
- Sponsor
- ד"ר דפנה יהב
- Start
- Feb 2021
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ascorbic acid, amoxicillin + clavulanate, ceftriaxone, azithromycin, hydrocortisone and 5 more in community-acquired pneumonia (CAP), coronavirus disease 2019 (COVID-19) and pneumonia (14 arms), sponsored by ד"ר דפנה יהב. Primary endpoint: 90-day mortality. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
ascorbic acidamoxicillin + clavulanateceftriaxoneazithromycinhydrocortisone
03
Conditions
community-acquired pneumonia (CAP)coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on MOH_2022-08-14_009900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-14_009900.